Diagnostic-driven therapies do not underperform because the science falls short.
They underperform when the patient journey break down.
Across real-world healthcare systems, identifying eligible patients is rarely straightforward. Testing occurs across multiple laboratories and institutions, results emerge at different stages of care, and interpretation is shared across clinicians, pathologists, and multidisciplinary teams. By the time eligibility is fully understood, treatment decisions are often already underway. This complexity makes early patient identification across the patient journey difficult to achieve in practice.
The challenge is not a lack of data.
It is the inability to see where opportunity exists while action can still make a difference.
Unlocking the full potential of diagnostic-driven therapies therefore depends on more than innovation alone. It depends on understanding where patients are progressing through the pathway, where clinical practice gaps are emerging, and where intervention can still influence therapy uptake.
Visibility into the patient journey is the first step to therapy adoption
When diagnostic-driven therapies fail to achieve their full clinical or commercial potential, attention often turns to downstream factors such as awareness, engagement, or prescribing behaviour.
But many of the most significant barriers occur much earlier in the patient journey.
Eligible patients may be identified too late, diagnostic pathways may stall, or treatment opportunities may narrow before the appropriate intervention occurs. In complex healthcare systems, these gaps are rarely caused by a single failure point. They emerge across fragmented testing pathways, disconnected workflows, and delays between diagnostic insight and clinical action.
The result: missed opportunities across the patient journey to influence treatment decisions while the pathway is still open.
For biopharma teams, this creates a fundamental commercialization challenge. If eligible patients and adoption barriers cannot be identified early enough, even the most innovative therapies struggle to reach their full potential.
More data alone does not improve timing in the patient journey
Healthcare organizations have access to more data than ever before.
Claims data, retrospective analytics, market reporting, and prescribing insights all help explain what has already happened across the patient journey.
But diagnostic-driven commercialization depends on something different:
the ability to act while decisions are still forming.
Clinicians are continuously interpreting diagnostic results, evaluating treatment pathways, and determining the next step for each patient. Once that treatment decision window closes, opportunities to influence therapy selection become significantly harder to recover. This is why retrospective targeting is no longer enough.
What biopharma teams need instead is decision-ready intelligence - intelligence grounded in real-world diagnostic activity that reveals where opportunities exist while intervention is still possible.
By translating diagnostic and healthcare data into decision-ready intelligence, it becomes possible to:
- Identify where eligible patients are emerging,
- Expose clinical practice gaps across the patient journey,
- Understand which HCPs and labs are actively managing eligible patients,
- Prioritize action where it can still make a difference to therapy uptake.
This shifts commercialization from retrospective reporting to prioritization driven by real diagnostic activity.
The treatment decision window defines outcomes across the patient journey
In diagnostic-driven therapies, timing is not a secondary consideration. It is central to adoption.
Patient identification happens within a sequence of clinical and diagnostic decisions that ultimately determine whether an eligible patient receives the right therapy.
When insight arrives early enough, clinicians have the opportunity to evaluate options with confidence. When visibility comes too late, treatment pathways have already advanced and opportunities for intervention narrow significantly.
This is why the treatment decision window matters. The value of intelligence is not simply in what it reveals, but when it becomes actionable.
From diagnostic intelligence to coordinated action
Visibility alone does not improve therapy uptake.
Unlocking the full potential of diagnostic-driven therapies requires intelligence and engagement to operate as a connected system - linking insight directly to timely action.
At Diaceutics, diagnostic and healthcare data from across an extensive, lab‑anchored data ecosystem is transformed into decision-ready intelligence that reveals where patient opportunities exist, where pathways are slowing, and where intervention can still influence adoption.
That intelligence then activates timely, targeted engagement within the treatment decision window through Physician Engage. HCPs and laboratories shaping care can be identified within 24 hours of a diagnostic event, enabling engagement while treatment decisions are still forming and the information is directly relevant to the patient in front of them.
This allows biopharma teams to:
- Prioritize resources based on real diagnostic activity,
- Align engagement to active patient pathways
- Support HCP confidence in complex treatment decisions,
- Intervene where practice gaps are limiting therapy adoption.
The result is not broader outreach. It is coordinated action at the moment it matters most.
Closing practice gaps before the opportunity is lost
Unlocking the full potential of diagnostic-driven therapies does not begin after treatment decisions are made. It begins by understanding where the patient journey breaks, where eligible patients are at risk of being missed, and where intervention can still change the outcome.
When decision-ready intelligence and timely engagement work together, clinical practice gaps can be identified earlier, intervention becomes more precise, and more eligible patients receive the therapies designed for them.
That is how diagnostic intelligence becomes commercial action.
Meet Diaceutics at ASCO 2026
Meet the Diaceutics team at ASCO Annual Meeting 2026 to discuss how decision-ready intelligence and timely, targeted engagement can help unlock the full potential of your diagnostic-driven therapies. Schedule a meeting here.
Discover how decision-ready intelligence and timely patient identification can unlock the full potential of your diagnostic-driven therapy. Explore our Intelligence Solutions
